Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance

Diabetes and Metabolism

Volumn 31, Issue 2, 2005, Pages 189-195

  Charpentier, G ^a   Fleury, F ^b   Dubroca, I ^b   Vaur, L ^b   Clerson, P ^c  

^a CENTRE HOSPITALIER SUD FRANCILIEN   (France)

^b SANOFI   (France)

^c Orgametrie   (France)

Author keywords

Compliance; Electronic pill box; Glimepiride; Treatment satisfaction; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG DOSE REGIMEN; ELECTRONIC PILL BOX; ELECTRONICS; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; INCIDENCE; MALE; MICROPROCESSOR; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PILL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

EID: 17744395778     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70185-4     Document Type: Article

References (25)

1. McNabb WL. Adherence in diabetes: can we define it and can we measure it? Diabetes Care, 1997, 20, 215-8.
2. Funnell MM, Anderson RM. MSJAM: the problem with compliance in diabetes. JAMA, 2000, 284, 1709.
3. Shobhana R, Begum R, Snehalatha C, Vijay V, Ramachandran A. Patients' adherence to diabetes treatment. J Assoc Physicians India, 1999, 47, 1173-5.
4. Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? Clin Pharmacol Ther, 1989, 46, 163-8.
5. Kruse W, Weber E: Dynamics of drug regimen compliance - its assessment by microprocessor-based monitoring. Eur J Clin Pharmacol, 1990, 38, 561-5.
6. Andrejak M, Genès N, Vaur L, Poncelet P, Clerson P, Carre A. Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimen. Am J Hypertens, 2000, 13, 184-90.
7. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care, 1997, 20, 1512-7.
8. Bradley C, Lewis KS. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med, 1990, 7, 445-51.
9. European Agency for the Evaluation of Medicinal Products. Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Diabetes Mellitus. London, 2002 (issued as CPMP/EWP/1080/00).
10. UK. Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352, 837-53.
11. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352, 854-65.
12. Donnan PT, Steinke DT, Newton RW, Morris AD for the DARTS/ MEMO Collaboration. Changes in treatment after the start of oral hypoglycaemic therapy in Type 2 diabetes: a population-based study. Diabet Med, 2002, 19, 606-10.
13. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med, 2002, 19, 279-84.
14. Evans JM, Donnan PT, Morris AD. Adherence to oral hypoglycaemic agents prior to insulin therapy in Type 2 diabetes. Diabet Med, 2002, 19, 685-8.
15. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care, 2002, 25, 1015-21.
16. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J, 2002, 95, 68-71.
17. Guillausseau PJ. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab, 2003, 29, 79-81.
18. Guerrero D, Rudd P, Bryant-Kosling C, Middleton BF. Antihypertensive medication-taking. Investigation of a simple regimen. Am J Hypertens, 1993, 6, 586-92.
19. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a Medicaid patient population with type 2 diabetes mellitus. Clin Ther, 2001, 23, 1311-20.
20. Draeger KE, Wernicke-Panten K, Lomp HJ, Schüler E, Rosskamp R. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl®): a double-blind comparison with glibenclamide. Horm Metab Res, 1996, 28, 419-25.
21. Dills DG, Schneider J, Glimepiride/Glyburide Research Group. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res, 1996, 28, 426-9.
22. Home PD, Lindholm A, Riist A. Insulin aspart vs human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: A randomized controlled trial. Diabet Med, 2000, 17, 762-70.
23. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. Diabet Med, 2001, 18, 619-25.
24. Reza M, Taylor CD, Towse K, Ward JD, Hendra TJ. Insulin improves well-being for selected elderly type 2 diabetic subjects. Diabetes Res Clin Pract, 2002, 55, 201-7.
25. Bech P, Moses R, Gomis R. The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy-naive type 2 diabetes: A placebo-controlled, multicentre study. Qual Life Res, 2003, 12, 413-25.